PT1991201T - Antibióticos nebulizados para terapia de inalação - Google Patents

Antibióticos nebulizados para terapia de inalação

Info

Publication number
PT1991201T
PT1991201T PT77033553T PT07703355T PT1991201T PT 1991201 T PT1991201 T PT 1991201T PT 77033553 T PT77033553 T PT 77033553T PT 07703355 T PT07703355 T PT 07703355T PT 1991201 T PT1991201 T PT 1991201T
Authority
PT
Portugal
Prior art keywords
nebulised
antibiotics
inhalation therapy
inhalation
therapy
Prior art date
Application number
PT77033553T
Other languages
English (en)
Inventor
Keller Manfred
Akkar Aslihan
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of PT1991201T publication Critical patent/PT1991201T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT77033553T 2006-02-10 2007-02-08 Antibióticos nebulizados para terapia de inalação PT1991201T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06002734 2006-02-10

Publications (1)

Publication Number Publication Date
PT1991201T true PT1991201T (pt) 2018-06-12

Family

ID=36607472

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77033553T PT1991201T (pt) 2006-02-10 2007-02-08 Antibióticos nebulizados para terapia de inalação

Country Status (19)

Country Link
US (1) US20090025713A1 (pt)
EP (1) EP1991201B1 (pt)
JP (1) JP2009526003A (pt)
CN (1) CN101389313A (pt)
AU (1) AU2007213983B2 (pt)
BR (1) BRPI0707641A2 (pt)
CA (1) CA2641827A1 (pt)
CY (1) CY1120284T1 (pt)
DK (1) DK1991201T3 (pt)
ES (1) ES2671342T3 (pt)
HU (1) HUE037773T2 (pt)
LT (1) LT1991201T (pt)
MX (1) MX2008010222A (pt)
PL (1) PL1991201T3 (pt)
PT (1) PT1991201T (pt)
RU (1) RU2008136460A (pt)
SI (1) SI1991201T1 (pt)
TR (1) TR201807714T4 (pt)
WO (1) WO2007090646A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883031B2 (en) * 2003-05-20 2011-02-08 James F. Collins, Jr. Ophthalmic drug delivery system
US8545463B2 (en) * 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
EP2030644A1 (en) * 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20090212133A1 (en) * 2008-01-25 2009-08-27 Collins Jr James F Ophthalmic fluid delivery device and method of operation
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
AU2009241628A1 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
WO2010048341A1 (en) 2008-10-22 2010-04-29 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
US20100209538A1 (en) * 2009-02-18 2010-08-19 Cipolla David C Ph-modulated formulations for pulmonary delivery
PL2248517T3 (pl) * 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
WO2011022075A1 (en) * 2009-08-19 2011-02-24 Mpex Pharmaceuticals, Inc. Use of aerosolized antibiotics for treating chronic obstructive pulmonary disease
AU2015275224C1 (en) * 2009-09-04 2017-11-16 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
WO2011104981A1 (ja) * 2010-02-25 2011-09-01 参天製薬株式会社 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用
AU2011278693B2 (en) * 2010-07-12 2015-02-19 Xellia Pharmaceuticals Aps Treatment of lung infections by administration of Tobramycin by aerolisation
CA2805426C (en) 2010-07-15 2020-03-24 Corinthian Ophthalmic, Inc. Drop generating device
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
CA2805635A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2012170677A1 (en) 2011-06-07 2012-12-13 Parion Sciences, Inc. Methods of treatment
EP2790619A1 (en) 2011-12-12 2014-10-22 Corinthian Ophthalmic, Inc. Ejector mechanism, ejector device, and methods of use
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
WO2015066282A1 (en) * 2013-10-30 2015-05-07 Inspirx Llc Inhaled aerosolized immuno-chemotherapy for the treatment of mdr tb
HUE047319T2 (hu) 2014-02-10 2020-04-28 Respivant Sciences Gmbh Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
ES2894741T3 (es) 2015-06-10 2022-02-15 Stamford Devices Ltd Generación de aerosol
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
LT3463280T (lt) * 2016-05-31 2022-09-26 Spexis Ag Beta plaukų segtuko struktūros peptido mimetikas, pasižymintis elastazės slopiklio aktyvumu ir jo aerozolinės vaisto formos
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
AU2017298202A1 (en) * 2016-07-16 2019-02-07 Lauranell Harrison Burch Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN107669636A (zh) * 2016-09-30 2018-02-09 青岛大学 一种氨溴索喷雾剂
CA3037746A1 (en) 2016-10-07 2018-04-12 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN109419785A (zh) * 2017-08-31 2019-03-05 正大青春宝药业有限公司 一种鱼腥草提取物制剂及其应用
IT201900006104A1 (it) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN112569211A (zh) * 2019-09-27 2021-03-30 盈科瑞（天津）创新医药研究有限公司 一种吸入用加替沙星溶液及其制备方法
CN114948914B (zh) * 2022-06-30 2024-04-02 北京新领先医药科技发展有限公司 一种盐酸莫西沙星雾化吸入用溶液剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104899C (zh) * 1995-12-21 2003-04-09 美国辉瑞有限公司 可注射喹诺酮制剂
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
HU229310B1 (en) * 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6550472B2 (en) * 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
WO2003012565A1 (en) * 2001-07-31 2003-02-13 Chrysalis Technologies Incorporated Method and apparatus for generating a volatilized liquid
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
DE10239321B3 (de) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2007500239A (ja) * 2003-05-30 2007-01-11 アルザ・コーポレーシヨン 薬剤の肺投与の方法
EP1684720B1 (en) * 2003-11-17 2009-05-27 Nektar Therapeutics Introducing aerosol into a ventilator circuit
NZ548225A (en) * 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações

Also Published As

Publication number Publication date
ES2671342T3 (es) 2018-06-06
US20090025713A1 (en) 2009-01-29
RU2008136460A (ru) 2010-03-20
HUE037773T2 (hu) 2018-09-28
WO2007090646A1 (en) 2007-08-16
CN101389313A (zh) 2009-03-18
BRPI0707641A2 (pt) 2011-05-10
AU2007213983B2 (en) 2012-09-20
EP1991201B1 (en) 2018-03-28
MX2008010222A (es) 2008-10-17
DK1991201T3 (en) 2018-06-14
JP2009526003A (ja) 2009-07-16
SI1991201T1 (en) 2018-08-31
EP1991201A1 (en) 2008-11-19
AU2007213983A1 (en) 2007-08-16
CA2641827A1 (en) 2007-08-16
PL1991201T3 (pl) 2018-09-28
LT1991201T (lt) 2018-07-25
CY1120284T1 (el) 2019-07-10
TR201807714T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
LT1991201T (lt) Puškiami antibiotikai inhaliaciniam gydymui
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
EP2051760A4 (en) ADMINISTRATION OF ANTI-THERAPY
EP2046430A4 (en) ADMINISTRATION OF ANTI-THERAPY
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
EP3782688B8 (en) Respiratory apparatus
ZA200901376B (en) Trauma therapy
SI1973598T1 (sl) Naprava za terapijo z zdravilom, ki se aktivira s svetlobo
HUE038232T2 (hu) Inhalátor
IL195247A0 (en) Inhaler
IL236360A0 (en) Inhalable medicine
EP2054061A4 (en) COMBINATION THERAPY
ZA200806929B (en) Nebulizer formulation
GB2434754B (en) Inhaler
IL197125A0 (en) Drug combinations for treating airway diseases
EP2076239A4 (en) COMBINATION THERAPY
EP2123295A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA
AP2006000208S (en) Inhaler
AU311731S (en) Inhaler
GB2437806B (en) Novel therapeutic delivery system
GB0524945D0 (en) Medicament inhaler
GB0612693D0 (en) Inhaler
GB0613459D0 (en) Novel therapeutic delivery system
GB0608669D0 (en) Novel Therapeutic Delivery System
GB0607158D0 (en) Therapy